Kevin Xie, Chairman and CEO of China Renaissance, was invited to attend as a guest speaker at the 4^th Asia Sumit on Global Health (ASGH) co-hosted by the Government of the Hong Kong Special Administrative Region (HKSAR) and Hong Kong Trade Development Council (HKTDC) on 16-17 May 2024.

Speaking at the session “Healthcare Investment Making Positive Impact”, Kevin commented: “Over the past 10 or 15 years, we have clearly observed our whole economy is moving into a digital age, including healthcare and life sciences sectors. For instance, in the photon imaging industry, we have seen companies worldwide, including players from China, adopting digitization for the imaging results, the impact is clearly precision accuracy and efficiency that saves costs for payment system for hospital for patients. In addition to digitization, we have also entered to an intelligence era. In the AI space, technology has be seen in many areas, in particular drug discovery. Companies from the US have adopted AI technologies more than 10 years ago and technology has been upgraded to the latest level. Meanwhile in China, where companies are taking the lead in terms of AI drug discovery, impact is also very clear as it saves time and cost.”

Regarding the emerging areas in healthcare that have the potential for significant positive impact, Kevin said “One particular therapeutic area is the Central Nervous System (CNS), which relates to the brain. A lot of scientists, physicians and investors are focusing on recent years in the US. In China, there are also companies targeting neuron related diseases, to depression to Alzheimer. Progress are being made, but so far a lot of those diseases haven't been clinically treated or have reached solutions. There will still be a challenge for mankind to come in this area.”